Linezolid for the treatment of complicated drug-resistant tuberculosis: A systematic review and meta-analysis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 4, 2012, Pages 447-454

  Cox, Helen ^a,b   Ford, N ^a,c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Linezolid; Resistance; Tuberculosis

Indexed keywords

ISONIAZID;

ANEMIA; BONE MARROW SUPPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INFECTION COMPLICATION; META ANALYSIS; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACETAMIDES; ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; OXAZOLIDINONES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84858657770     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0451     Document Type: Review

References (36)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 2010.
2. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
3. Jacobson K R, Tierney D B, Jeon C Y, Mitnick C D, Murray M B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
4. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009; 4: e6914.
5. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011. WHO/HTM/TB/2011.3. Geneva, Switzerland: WHO, 2011.
6. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-1807.
7. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: WHO, 2008.
8. Garcia-Tapia A, Rodriguez J C, Ruiz M, Royo G. Action of fluoroquinolones and linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis. Chemotherapy 2004; 50: 211-213. (Pubitemid 39541230)
9. Huang T S, Liu Y C, Sy C L, Chen Y S, Tu H Z, Chen B C. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother 2008; 52: 2226-2227.
10. Anger H A, Dworkin F, Sharma S, Munsiff S S, Nilsen D M, Ahuja S D. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010; 65: 775-783.
11. Migliori G B, Eker B, Richardson M D, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
12. Park I N, Hong S B, Oh Y M, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58: 701-704. (Pubitemid 44288145)
13. Linezolid. Tuberculosis (Edinb) 2008; 88: 122-125.
14. Stroup D F, Berlin J A, Morton S C, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012. (Pubitemid 30214957)
15. Newcombe R G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873-890. (Pubitemid 28185166)
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
17. Rucker G, Schwarzer G, Carpenter J R, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008; 8: 79.
18. Eker B, Ortmann J, Migliori G B, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14: 1700-1706.
19. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom W N. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008; 134: 187-192. (Pubitemid 352008783)
20. Nam H S, Koh W J, Kwon O J, Cho S N, Shim T S. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents 2009; 33: 92-93.
21. Koh W J, Kwon O J, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-391.
22. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-185.
23. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - a report of ten cases. J Infect 2006; 52: 92-96.
24. Yew W W, Chau C H, Wen K H. Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008; 12: 345-346. (Pubitemid 351361909)
25. Jeon D S, Kim D H, Kang H S, et al. Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13: 594-600.
26. Udwadia Z F, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective. Eur Respir J 2010; 35: 936-938; author reply 8-40.
27. Schecter G F, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
28. Jeon D S, Shin D O, Park S K, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci 2011; 26: 33-41.
29. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326. (Pubitemid 40139109)
30. Stalker D J, Jungbluth G L. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-1140. (Pubitemid 37357649)
31. Sterne J A, Sutton A J, Ioannidis J P, et al. Recommendations for examining and interpreting funnel plot asymmetry in metaanalyses of randomised controlled trials. BMJ 2011; 343: d4002.
32. Seung K J, Omatayo D B, Keshavjee S, Furin J J, Farmer P E, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS ONE 2009; 4: e7186.
33. Médecins Sans Frontières/International Union Against Tuberculosis and Lung Disease. DR-TB drugs under the microscope: the sources and prices for drug-resistant tuberculosis medicines. Geneva, Switzerland: MSF, 2011.
34. Lee M, Min J, Carroll M, Eum S, Lee J, Kim S, et al. Clinical trial of the efficacy of linezolid in XDR pulmonary tuberculosis. The 41st Union World Conference on Lung Health, 11-15 November 2010, Berlin. Int J Tuberc Lung Dis 2010; 14 (Suppl 2): S56.
35. Padayatchi N, Saukkonen J, Villarino E, et al. Linezolid for MDR-TB treatment: the LiMiT study. The 41st Union World Conference on Lung Health, 11-15 November 2010, Berlin. Int J Tuberc Lung Dis 2010; 14 (Suppl 2): S3.
36. Alffenaar J W, van der Laan T, Simons S, et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 2011; 55: 1287-1289.